The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Cd80  -  CD80 antigen

Mus musculus

Synonyms: Activation B7-1 antigen, B7, B7-1, B7.1, B71, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cd80


High impact information on Cd80


Chemical compound and disease context of Cd80


Biological context of Cd80


Anatomical context of Cd80


Associations of Cd80 with chemical compounds

  • Rapid up-regulation of B7-1 expression, a unique response to CD21/CD35 and CD19 cross-linking, may be a particularly important effect of C3-containing ligands [20].
  • CONCLUSION: Blockade of the B7-CD28 costimulatory pathway by adenovirus-mediated CTLA-4Ig gene transfer is as effective as the recombinant fusion protein in treating established CIA, without the need for repeated administrations [21].
  • Both B7-1 and B7-2 were, however, highly expressed on the majority of islet-infiltrating inflammatory cells in NOD mice between days 7 and 12 after the administration of cyclophosphamide which results in accelerated beta cell destruction [22].
  • Although B7.1 mRNA was not upregulated above constitutive levels, MG treatment enhanced B7.1 glycoprotein expression on the macrophages, albeit to a lesser extent than B7 [23].
  • In the present study, we investigated whether the cytokines released after HSV-TK and GCV treatment could include the expression of the costimulatory molecules B7-1 and B7-2 and the adhesion molecule (ICAM)-1 in the tumor [24].

Physical interactions of Cd80


Regulatory relationships of Cd80

  • The addition of anti-gp39 blocked the up-regulated expression of B7-1 and partially blocked the up-regulated expression of B7-2 [28].
  • Flow cytometric analysis of dispersed lung cells showed that expression of IL-10 in the airway reduced the absolute number of Class II major histocompatibility complex (MHC)(+)/CD11c(+) (dendritic cells) and Class II MHC(+)/Mac-1(bright) (macrophages) cells expressing the costimulatory molecules B7.1 and B7.2 by 30% [29].
  • First, CTLA-4 specific monoclonal antibody was used to block B7-1-CTLA-4 interaction [4].
  • IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2 [30].
  • TLR2 and TLR4 differentially regulate B7-1 resulting in distinct cytokine responses to the mycoplasma superantigen MAM as well as to disease induced by Mycoplasma arthritidis [31].

Other interactions of Cd80

  • In sharp contrast, spontaneous diabetes is exacerbated in both B7-1/B7-2-deficient and CD28-deficient NOD mice [1].
  • We have also detected a higher ratio of CD4+/CD8+ T cells and increased expression of B7.1/B7.2 on B cells and antigen-presenting cells in IFNB knockout mice [32].
  • This splice variant of CTLA4, named ligand-independent CTLA4 (liCTLA4), lacks exon 2 including the MYPPPY motif essential for binding to the costimulatory ligands B7-1 and B7-2. liCTLA4 is expressed as a protein in primary T cells and strongly inhibits T cell responses by binding and dephosphorylating the TcRzeta chain [33].
  • Significantly, expression of B7.1 or B7.2 without additional accessory molecules led to very high production of interleukin (IL)-4, which contrasted with minimal IL-4 production elicited by conventional antigen presenting cells (APC) [34].
  • To assess the role of the two ligands for CD28, B7.1 and B7.2, IL-10 KO mice were treated with alphaIL-12 plus alphaB7.1 or alphaB7.2 or the combination of all three antibodies [35].

Analytical, diagnostic and therapeutic context of Cd80

  • Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines [36].
  • In vivo, C1498/B7-1 grew progressively after subcutaneous injection, whereas C1498/B7-2 completely regressed after transient growth in naive mice [4].
  • Flow cytometry revealed that CD11b(+) and MHC class II(+) graft infiltrating cells expressed B7-1 more than B7-2, whereas B7-2 expression was predominant in CD11b(-) cells at 4 and 8 weeks [37].
  • Grafts in wild-type recipients showed macrophage, recipient MHC class II, and B7 molecule co-localization by immunohistochemistry to GAD lesions [37].
  • These data support the potential clinical utility of combined gene therapy using IL-12- and B7.1-engineered autologous cells (tumor or fibroblasts) as a vaccine to elicit specific anti-tumor immunity [38].


  1. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Salomon, B., Lenschow, D.J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., Bluestone, J.A. Immunity (2000) [Pubmed]
  2. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. Stremmel, C., Greenfield, E.A., Howard, E., Freeman, G.J., Kuchroo, V.K. J. Exp. Med. (1999) [Pubmed]
  3. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. Racke, M.K., Scott, D.E., Quigley, L., Gray, G.S., Abe, R., June, C.H., Perrin, P.J. J. Clin. Invest. (1995) [Pubmed]
  4. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. LaBelle, J.L., Hanke, C.A., Blazar, B.R., Truitt, R.L. Blood (2002) [Pubmed]
  5. The B7 family revisited. Greenwald, R.J., Freeman, G.J., Sharpe, A.H. Annu. Rev. Immunol. (2005) [Pubmed]
  6. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Salomon, B., Bluestone, J.A. Annu. Rev. Immunol. (2001) [Pubmed]
  7. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Kuchroo, V.K., Das, M.P., Brown, J.A., Ranger, A.M., Zamvil, S.S., Sobel, R.A., Weiner, H.L., Nabavi, N., Glimcher, L.H. Cell (1995) [Pubmed]
  8. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Chen, L., Ashe, S., Brady, W.A., Hellström, I., Hellström, K.E., Ledbetter, J.A., McGowan, P., Linsley, P.S. Cell (1992) [Pubmed]
  9. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. Herold, K.C., Vezys, V., Koons, A., Lenschow, D., Thompson, C., Bluestone, J.A. J. Immunol. (1997) [Pubmed]
  10. B7 requirements for primary and secondary protein- and polysaccharide-specific Ig isotype responses to Streptococcus pneumoniae. Wu, Z.Q., Khan, A.Q., Shen, Y., Schartman, J., Peach, R., Lees, A., Mond, J.J., Gause, W.C., Snapper, C.M. J. Immunol. (2000) [Pubmed]
  11. Involvement of altered B7 expression in dioxin immunotoxicity: B7 transfection restores the CTL but not the autoantibody response to the P815 mastocytoma. Prell, R.A., Kerkvliet, N.I. J. Immunol. (1997) [Pubmed]
  12. Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity. Reiser, H., Schneeberger, E.E. Eur. J. Immunol. (1996) [Pubmed]
  13. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. Sojka, D.K., Donepudi, M., Bluestone, J.A., Mokyr, M.B. J. Immunol. (2000) [Pubmed]
  14. The costimulatory genes Cd80 and Cd86 are linked on mouse chromosome 16 and human chromosome 3. Reeves, R.H., Patch, D., Sharpe, A.H., Borriello, F., Freeman, G.J., Edelhoff, S., Disteche, C. Mamm. Genome (1997) [Pubmed]
  15. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Borriello, F., Sethna, M.P., Boyd, S.D., Schweitzer, A.N., Tivol, E.A., Jacoby, D., Strom, T.B., Simpson, E.M., Freeman, G.J., Sharpe, A.H. Immunity (1997) [Pubmed]
  16. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., Horton, H.F., Fouser, L., Carter, L., Ling, V., Bowman, M.R., Carreno, B.M., Collins, M., Wood, C.R., Honjo, T. J. Exp. Med. (2000) [Pubmed]
  17. Perinatal blockade of b7-1 and b7-2 inhibits clonal deletion of highly pathogenic autoreactive T cells. Gao, J.X., Zhang, H., Bai, X.F., Wen, J., Zheng, X., Liu, J., Zheng, P., Liu, Y. J. Exp. Med. (2002) [Pubmed]
  18. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Swallow, M.M., Wallin, J.J., Sha, W.C. Immunity (1999) [Pubmed]
  19. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Orabona, C., Grohmann, U., Belladonna, M.L., Fallarino, F., Vacca, C., Bianchi, R., Bozza, S., Volpi, C., Salomon, B.L., Fioretti, M.C., Romani, L., Puccetti, P. Nat. Immunol. (2004) [Pubmed]
  20. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. Kozono, Y., Abe, R., Kozono, H., Kelly, R.G., Azuma, T., Holers, V.M. J. Immunol. (1998) [Pubmed]
  21. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Quattrocchi, E., Dallman, M.J., Feldmann, M. Arthritis Rheum. (2000) [Pubmed]
  22. Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse. Stephens, L.A., Kay, T.W. Int. Immunol. (1995) [Pubmed]
  23. Microparticulate beta-glucan upregulates the expression of B7.1, B7.2, B7-H1, but not B7-DC on cultured murine peritoneal macrophages. Hunter, K.W., DuPre', S., Redelman, D. Immunol. Lett. (2004) [Pubmed]
  24. Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Ramesh, R., Munshi, A., Abboud, C.N., Marrogi, A.J., Freeman, S.M. Cancer Gene Ther. (1996) [Pubmed]
  25. DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Chang, Y., Yap, S., Ge, X., Piganelli, J., Bertera, S., Giannokakis, N., Mathews, C., Prud'homme, G., Trucco, M. Gene Ther. (2005) [Pubmed]
  26. The influence of the major histocompatibility complex on development of autoimmune diabetes in RIP-B7.1 mice. Wong, F.S., Du, W., Thomas, I.J., Wen, L. Diabetes (2005) [Pubmed]
  27. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Donepudi, M., Jovasevic, V.M., Raychaudhuri, P., Mokyr, M.B. Cancer Immunol. Immunother. (2003) [Pubmed]
  28. Studies on the interdependence of gp39 and B7 expression and function during antigen-specific immune responses. Roy, M., Aruffo, A., Ledbetter, J., Linsley, P., Kehry, M., Noelle, R. Eur. J. Immunol. (1995) [Pubmed]
  29. Interleukin-10 gene transfer to the airway regulates allergic mucosal sensitization in mice. Stämpfli, M.R., Cwiartka, M., Gajewska, B.U., Alvarez, D., Ritz, S.A., Inman, M.D., Xing, Z., Jordana, M. Am. J. Respir. Cell Mol. Biol. (1999) [Pubmed]
  30. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. Stack, R.M., Lenschow, D.J., Gray, G.S., Bluestone, J.A., Fitch, F.W. J. Immunol. (1994) [Pubmed]
  31. TLR2 and TLR4 differentially regulate B7-1 resulting in distinct cytokine responses to the mycoplasma superantigen MAM as well as to disease induced by Mycoplasma arthritidis. Mu, H.H., Humphreys, J., Chan, F.V., Cole, B.C. Cell. Microbiol. (2006) [Pubmed]
  32. Upregulation of B7 molecules (CD80 and CD86) and exacerbated eosinophilic pulmonary inflammatory response in mice lacking the IFN-beta gene. Matheu, V., Treschow, A., Navikas, V., Issazadeh-Navikas, S. J. Allergy Clin. Immunol. (2003) [Pubmed]
  33. An autoimmune disease-associated CTLA4 splice variant lacking the B7 binding domain signals negatively in T cells. Vijayakrishnan, L., Slavik, J.M., Illés, Z., Rainbow, D., Peterson, L.B., Sharpe, A.S., Wicker, L.S., Kuchroo, V.K. Novartis Found. Symp. (2005) [Pubmed]
  34. Intercellular adhesion molecule-1 inhibits interleukin 4 production by naive T cells. Luksch, C.R., Winqvist, O., Ozaki, M.E., Karlsson, L., Jackson, M.R., Peterson, P.A., Webb, S.R. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  35. Contribution of interleukin-12 (IL-12) and the CD28/B7 and CD40/CD40 ligand pathways to the development of a pathological T-cell response in IL-10-deficient mice. Wille, U., Villegas, E.N., Craig, L., Peach, R., Hunter, C.A. Infect. Immun. (2002) [Pubmed]
  36. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Dunussi-Joannopoulos, K., Dranoff, G., Weinstein, H.J., Ferrara, J.L., Bierer, B.E., Croop, J.M. Blood (1998) [Pubmed]
  37. Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2. Furukawa, Y., Mandelbrot, D.A., Libby, P., Sharpe, A.H., Mitchell, R.N. Am. J. Pathol. (2000) [Pubmed]
  38. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Zitvogel, L., Robbins, P.D., Storkus, W.J., Clarke, M.R., Maeurer, M.J., Campbell, R.L., Davis, C.G., Tahara, H., Schreiber, R.D., Lotze, M.T. Eur. J. Immunol. (1996) [Pubmed]
WikiGenes - Universities